8.71
전일 마감가:
$8.82
열려 있는:
$8.79
하루 거래량:
446.85K
Relative Volume:
0.52
시가총액:
$439.98M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.6559
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+16.76%
1개월 성능:
+6.74%
6개월 성능:
+14.91%
1년 성능:
-28.90%
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.71 | 445.54M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
2025-02-07 | 재개 | Raymond James | Outperform |
2024-11-15 | 재개 | Morgan Stanley | Overweight |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-06-07 | 개시 | Goldman | Buy |
2024-03-11 | 개시 | H.C. Wainwright | Buy |
2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-02-21 | 재개 | Raymond James | Outperform |
2023-11-01 | 개시 | Stifel | Buy |
2023-06-02 | 개시 | Robert W. Baird | Outperform |
2022-06-23 | 개시 | Berenberg | Buy |
2021-12-15 | 개시 | Wedbush | Neutral |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2020-12-16 | 개시 | UBS | Buy |
2020-06-25 | 재개 | BofA/Merrill | Buy |
2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
2019-06-14 | 재개 | Raymond James | Outperform |
2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
2018-11-08 | 재확인 | BofA/Merrill | Neutral |
2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
2018-05-09 | 재확인 | Barclays | Overweight |
2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2018-02-13 | 개시 | Mizuho | Neutral |
2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO Inc. Facing Inflection Point in Trend AnalysisJuly 2025 WrapUp & Verified High Yield Trade Plans - kangso.co.kr
Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser
Can REGENXBIO Inc. hit a new high this monthJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
Is a relief rally coming for REGENXBIO Inc. holdersJuly 2025 Outlook & Technical Pattern Alert System - Newser
When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Will breakout in REGENXBIO Inc. lead to full recoveryJuly 2025 Macro Moves & Verified Entry Point Signals - Newser
Are Options Traders Betting on a Big Move in Regenxbio Stock? - TradingView
What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Raymond James Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results By Investing.com - Investing.com South Africa
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener
Regenxbio: Chardan Capital maintains Buy, PT raised to $52 from $52. - AInvest
Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest
Regenxbio Inc (RGNX) Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... By GuruFocus - Investing.com Canada
Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser
Regenxbio: Q2 Earnings Snapshot - Stamford Advocate
Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest
Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada
Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks
Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
자본화:
|
볼륨(24시간):